Tools for Practice Outils pour la pratique


#57 Is colchicine an effective alternative to NSAIDs for the treatment of acute gout?


CLINICAL QUESTION
QUESTION CLINIQUE
For patients with acute gout, is colchicine an effective treatment, and when would its use be indicated?


BOTTOM LINE
RÉSULTAT FINAL
Colchicine is a reasonable option for the treatment of acute gout, especially in patients in whom NSAIDs are contraindicated. Optimal dosing that balances treatment benefit with potential adverse events remains to be determined, but low dose is recommended.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Two Randomized Controlled Trials (RCTs)1,2 provide the best-available evidence to answer this question: 
  • Industry-funded trial1 with unclear risk of bias: 
    • Population: 575 patients with gout randomized in a blinded fashion to low- or high-dose colchicine or placebo for the next gout attack (185 patients had a gout attack requiring study drug). 
    • Interventions: 
      • Low-dose: 1.2 mg, then 0.6 mg one hour later (1.8 mg total). 
      • High-dose: 1.2 mg, then 0.6 mg every one hour x 6 hours (4.8 mg total). 
    • Primary outcome: Achieved ≥50% reduction in pain at 24 hours without use of ‘rescue’ medicine. 
      • Statistically significant benefit with low-dose colchicine versus placebo (37.8% vs. 15.5%, Number Needed to Treat (NNT)=5). 
      • No difference between low- and high-dose colchicine (37.8% versus 32.7%). 
    • Adverse events: 
      • Low-dose colchicine had statistically significantly fewer adverse events than high-dose. 
        • Diarrhea: 26% versus 77%, NNT=2. 
        • Nausea: 4% versus 17%, NNT=8. 
  • The only other placebo-controlled trial2 of colchicine for acute gout showed a similar benefit (NNT=3), however: 
    • High-dose regimen (1 mg, followed by 0.5 mg every two hours until complete pain relief or adverse events) resulted in 100% adverse event rate (vomiting or diarrhea). 
  • Systematic reviews found no other RCTs of colchicine.3,4 
Context:   
  • The latest guidelines5,6 recommend low-dose colchicine, NSAIDs, or oral corticosteroids for acute gout 
  • No published studies have directly compared colchicine to NSAIDs or corticosteroids,3,4 and no specific NSAID appears superior to another NSAID in treating acute gout.7 
  • Caution is recommended when using: 
    • NSAIDs in patients with hypertension, cardiovascular or renal impairment, or those at risk of gastrointestinal events.8 
    • Colchicine in patients with renal or hepatic impairment and patients on CYP3A4 inhibitors (clarithromycin, calcium-channel blockers, oral antifungals, and many more) or P-glycoprotein inhibitors (e.g. cyclosporine).8,9 
update jan 13 2018 by ricky


Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Christina Korownyk MD CCFP
  • Michael R Kolber MD CCFP MSc

1. Terkeltaub RA, Furst DE, Bennett K, et al. Arthritis Rheum. 2010; 62:1060-8.

2. Ahern MJ, Reid C, Gordon TP, et al. Aust N Z J Med. 1987; 17:301-4.

3. van Echteld I, Wechalekar MD, Schlesinger N, et al. Cochrane Database Syst Rev. 2014; 8:CD006190.

4. Shekelle PG, Newberry SJ, FitzGerald JD, et al. Ann Intern Med. 2017; 166:37-51.

5. Qaseem A, Harris RP, Forciea MA, et al. Ann Intenr Med. 2017; 166:58-68.

6. Richette P, Doherty M, Pascual E, et al. Ann Rheum. 2017; 76:29-42.

7. van Durme CM, Wechalekar MD, Buchbinder R, et al. Cochrane Database Syst Rev. 2014; 9:CD010120.

8. Keenan RT, O’Brien WR, Lee KH, et al. Am J Med. 2011; 124:155-63.

9. e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2014 [revised 2014 Sept; cited 2014 Dec 4]. Colchicine (CPhA Monograph) [product monograph].

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.